DISCLOSURE
Breast Cancer, Cancer
BREAST CANCER, CANCER
This work was partially supported by grants from the Swedish Breast Cancer Association, Swedish Cancer Foundation (19 0507 Pj), Roche AB Sweden, and the Percy Falk Foundation. Fredrik Frejd and Joachim Feldwisch are employees and own shares in Affibody AB. Jens Sörensen received clinical advisor remunerations from Affibody AB. Johan Hartman obtained speaker’s honoraria or advisory board remunerations from Roche, Novartis, Pfizer, Eli Lilly, MSD, Veracyte, and ExactSciences and received institutional research support from Cepheid, Roche, and Novartis. No other potential conflict of interest relevant to this article was reported.